What should personalized, precision treatment of cancer look like in the future?
We know that people are different, their tumors are different, and they respond differently to different therapies. Medical teams of the future might be able to create a ?“virtual twin” of a person and their tumor. Then, by tapping supercomputers, physician-led teams could simulate how tumor cells behave to test millions (or billions) of possible treatment combinations. Ultimately, the best combinations might offer clues towards a personalized, effective treatment plan.
Sound like wishful thinking? The first steps towards this vision have been undertaken by a multi-institution research collaboration that includes Jonathan Ozik and Nicholson Collier, computational scientists at the U.S. Department of Energy’s Argonne National Laboratory.
The research team, which includes collaborators at Indiana University and the University of Vermont Medical Center, brought the power of high-performance computing to the thorny challenge of improving cancer immunotherapy. The team tapped twin supercomputers at Argonne and the University of Chicago, finding that high-performance computing can yield clues in fighting cancer, as discussed in a June 7 article published in Molecular Systems Design and Engineering.
“With this new approach, researchers can use agent-based modeling in more scientifically robust ways.” — Nicholson Collier, computational scientist at Argonne and the University of Chicago
Standing up to cancer
Cancer immunotherapy is a promising treatment that realigns your immune system to reduce or eliminate cancer cells. The therapy, however, helps only 10 to 20 percent of patients — partly because the way in which cancer cells and immune cells mingle is complex and poorly understood. Proven rules are scarce.
To begin uncovering the rules of immunotherapy, the team turned to a set of three tools:
- Agent-based modeling, which predicted the behavior of individual ?“agents” – cancer and immune cells, in this case
- Argonne’s award-winning workflow technology to take full advantage of the supercomputers
- A guiding framework to explore models and dynamically direct and track results
The trio operate in a hierarchy. The framework, developed by Ozik, Collier, Argonne colleagues, and Gary An, a surgeon and professor at the University of Vermont Medical Center, is called Extreme-scale Model Exploration with Swift (EMEWS). It oversees the agent-based model and the workflow system, the Swift/T parallel scripting language, developed at Argonne and the University of Chicago.
What is unique about this combination of tools? ?“We are helping more people in a variety of computational science fields to do large-scale experimentation with their models,” said Ozik, who — like Collier — holds a joint appointment at the University of Chicago. ?“Building a model is fun. But without supercomputers, it is difficult to really understand the full potential of how models can behave.”
The Latest on: Personalized medicine
[google_news title=”” keyword=”personalized medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized medicine
- Personalized Medicine Market Size to Surpass USD 1,233.23 Bn by 2033on February 22, 2024 at 8:15 am
The global personalized medicine market size is expected to surpass around USD 1,233.23 billion by 2033, increasing from USD 578.21 billion in 2023, According to .Ottawa, Feb. 22, 2024 (GLOBE NEWSWIRE ...
- New cancer research for personalized careon February 22, 2024 at 5:38 am
These findings are expected to streamline the process of matching an immunotherapy treatment to a specific patient since it is very important to identify in advance those patients who will react to a ...
- Genetics of Osteoporosis: Perspectives for Personalized Medicineon February 21, 2024 at 4:00 pm
With this in mind, we shall discuss the potential implications of osteoporosis genetics on personalized medicine with a focus on individualized drug therapy. Our basic premises are: Causative ...
- Long Read Sequencing Market to Reach $5,142.3 Million by 2030 Owing To Increasing Demand for Personalized Medicine | Says Coherent Market Insightson February 20, 2024 at 1:04 am
Burlingame, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Coherent Market Insights published a report, titled, Global Long Read Sequencing Market, By Technology (Single Molecule Real-Time (SMRT) Sequencing, ...
- Unlocking the Potential of AI-Driven Biomarkers: A New Era in Personalized Cancer Careon February 15, 2024 at 9:46 am
As we witness the emergence of more treatments, personalized medicine becomes crucial to tailoring therapies to each individual patient. However, the lack of effective cancer treatment-specific ...
- Researchers edge closer to delivering personalized medicine to cancer patientson February 14, 2024 at 3:59 am
For the first time, Purdue researchers prove that measuring mechanical motions in living cancer tissues is a viable and promising approach for predicting chemoresistance ...
- Purdue researchers edge closer to delivering personalized medicine to cancer patientson February 13, 2024 at 8:48 am
Chemotherapy can save lives, but often a cancer patient may be resistant to their prescribed chemotherapy, which costs the patient valuable time. Chemoresistance is a topic that researchers need to ...
- Personalized Medicine Is Revolutionizing the Role of Pharma Companies in the Healthcare Landscapeon February 1, 2024 at 9:25 am
Personalized medicine is quite possibly the greatest healthcare innovation of our time. It offers the chance to improve and even save the lives of millions of people. But it also presents ...
- Personalized Medicine in Oncologyon January 28, 2024 at 4:00 pm
Current advances in the biology of cancer and emergence of new tools for genome analysis have opened clinical perspectives in oncology, generally termed as 'personalized medicine'. This broad term ...
via Bing News